16 September 2026 editorial review · Item
MiniMed Vivera (next-generation SmartGuard algorithm): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Thriving evidence review — 16 September 2026
Record: MiniMed Vivera (next-generation SmartGuard algorithm)
Scope and findings:
- Read September company launch/pipeline announcement; corrected timing/European access and separated submission, CE marking, enrollment and approval. No new efficacy inferred.
- Live GATEWAY registry status ACTIVE_NOT_RECRUITING, actual 389, estimated primary/completion January 2027; updated enrollment language independently of company Vivera milestone.
Primary sources checked:
Limits: The review is restricted to the scopes above. Historical efficacy estimates, editorial scoring and country-specific access were not fully reverified unless expressly stated. A manufacturer or conference report retains that evidence level.
Thriving evidence review — 16 September 2026
Additional second-pass scope: Unreleased-product scores explicitly provisional; commercial access0; removed trial-entry age from approved-age field. Omnipod6 TIR remains observed sponsor-reported33-person age14+ T1D subgroup, not all132randomized participants.
Primary sources checked:
Limits: Only the specific claims and scoring interpretation above were revisited. This does not revalidate every historical outcome or regional access claim.